Publisher
Springer Nature Singapore
Reference7 articles.
1. Chan AW, Chau SL, Tong JH, et al. The landscape of actionable molecular alterations in immunomarker defined large-cell carcinoma of the lung. J Thorac Oncol. 2019;14:1213–22.
2. Ooi R, Tobino K, Sakabe M, et al. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. Respir Med Case Rep. 2020;31:101197.
3. Okabe N, Mine H, Takagi H, et al. Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report. Thorac Cancer. 2021:1141–4.
4. Kanashiki M, Tomizawa T, Yamaguchi I, et al. Volume doubling time of lung cancers detected in a chest radiograph mass screening program: comparison with CT screening. Oncol Lett. 2012;4:513–6.
5. Henschke CI, Yankelevitz DF, Yip R, et al. Lung cancers diagnosed at annual CT screening: volume doubling times. Radiology. 2012;263:578–83.